Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Goel U, et al. Among authors: charalampous c. Blood Cancer J. 2024 Mar 26;14(1):55. doi: 10.1038/s41408-024-01039-1. Blood Cancer J. 2024. PMID: 38531841 Free PMC article.
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma.
Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Blood Adv. 2022 May 10;6(9):2763-2772. doi: 10.1182/bloodadvances.2022007052. Blood Adv. 2022. PMID: 35235951 Free PMC article.
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma.
Charalampous C, Goel U, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Buadi F, Kapoor P, Kourelis T, Warsame R, Hogan WJ, Kumar S. Charalampous C, et al. Bone Marrow Transplant. 2023 Jan;58(1):46-53. doi: 10.1038/s41409-022-01835-y. Epub 2022 Oct 6. Bone Marrow Transplant. 2023. PMID: 36203088 Free PMC article.
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Charalampous C, et al. Am J Hematol. 2023 Mar;98(3):413-420. doi: 10.1002/ajh.26806. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588396 Free article.
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.
Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Goel U, et al. Among authors: charalampous c. Blood Cancer J. 2023 Jan 11;13(1):11. doi: 10.1038/s41408-023-00785-y. Blood Cancer J. 2023. PMID: 36631454 Free PMC article. No abstract available.
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Blood Adv. 2023 Aug 22;7(16):4371-4380. doi: 10.1182/bloodadvances.2023009681. Blood Adv. 2023. PMID: 37603349 Free PMC article.
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Blood Cancer J. 2023 Dec 11;13(1):183. doi: 10.1038/s41408-023-00957-w. Blood Cancer J. 2023. PMID: 38072941 Free PMC article. No abstract available.
38 results